
Asymchem is a CDMO serving emerging biotech companies and specialty pharma.
asymchem.comCrawled Nov 20, 2026
Asymchem provides contract development and manufacturing services for pharmaceutical companies.
Asymchem successfully passes its first U.S. FDA Pre-Approval Inspection (PAI) for the Tianjin 4 TIDES manufacturing facility. The inspection, conducted between June 29 and July 2, 2026, covers the development and production operations at the TJ4 site. This milestone marks a key regulatory step for Asymchem’s expansion in pharmaceutical manufacturing.
Asymchem’s Dunhua 2 (DH2) facility in Jilin, a dedicated carbapenem active pharmaceutical ingredient (API) manufacturing site, passes its first US FDA Pre-Approval Inspection (PAI). The inspection, conducted between April 27–30, 2026, evaluates the site’s continuous manufacturing processes for carbapenem APIs. The PAI was completed under a short-notice review, marking a key milestone for Asymchem’s global CDMO operations.
Asymchem introduces a fully integrated commercial supply matrix for TIDES (Peptides and Oligonucleotides) at its TJ4 site in Tianjin, China. The new system combines expanded API manufacturing capacity, drug product facilities, and advanced process technologies for synthesis, purification, and commercial scale-up. This initiative aims to support partners throughout the development and production pipeline, from molecule to market.
Snapdragon Chemistry and Asymchem cancel their planned acquisition due to unresolved CFIUS mitigation terms. The U.S. Treasury’s Committee on Foreign Investment in the United States (CFIUS) required additional safeguards that neither party could agree upon. The deal, previously announced, now will not proceed as originally intended.
Asymchem Labs finalizes construction of two new production facilities in China, expanding its capacity in Dunhua and Tianjin. The company now operates additional manufacturing buildings at both locations, supporting its role as a contract development and manufacturing organization (CDMO). The upgrades align with growing demand for pharmaceutical production in the region.